SNY – Sanofi
SNY — Price & Float Short
—— Fair value
★ EPS beat
★ EPS miss
—— Target Price
Float Short %
Float Short %
0.33
Margin Of Safety %
34
Put/Call OI Ratio
1.04
EPS Next Q Diff
0.55
EPS Last/This Y
1.07
EPS This/Next Y
0.37
Price
42.7
Target Price
53.92
Analyst Recom
2.29
Performance Q
-7.22
Upside
-27.2%
Beta
0.31
Ticker: SNY
of 1
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2026-04-20 | SNY | 47.97 | 1.11 | 0.32 | 49057 |
| 2026-04-23 | SNY | 47.56 | 1.11 | 0.11 | 53063 |
| 2026-04-24 | SNY | 46.81 | 1.19 | 0.33 | 51942 |
| 2026-04-27 | SNY | 45.91 | 1.20 | 0.98 | 52161 |
| 2026-04-28 | SNY | 45.97 | 1.20 | 0.54 | 52805 |
| 2026-04-29 | SNY | 46.04 | 1.20 | 1.10 | 52895 |
| 2026-04-30 | SNY | 46.57 | 1.21 | 0.82 | 54701 |
| 2026-05-01 | SNY | 46.1 | 1.21 | 0.06 | 55824 |
| 2026-05-04 | SNY | 43.31 | 1.31 | 1.03 | 55308 |
| 2026-05-05 | SNY | 43.39 | 1.24 | 0.14 | 55494 |
| 2026-05-06 | SNY | 43.74 | 1.18 | 0.26 | 56449 |
| 2026-05-07 | SNY | 43.19 | 1.15 | 0.11 | 56833 |
| 2026-05-08 | SNY | 43.31 | 1.10 | 0.18 | 57242 |
| 2026-05-11 | SNY | 42.5 | 1.08 | 0.51 | 58160 |
| 2026-05-12 | SNY | 42.85 | 1.07 | 0.84 | 58391 |
| 2026-05-13 | SNY | 42.44 | 1.06 | 0.86 | 59576 |
| 2026-05-14 | SNY | 42.85 | 1.06 | 0.47 | 60839 |
| 2026-05-15 | SNY | 42.69 | 1.04 | 0.31 | 61626 |
| Date | Symbol | Latest | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2026-04-16 | SNY | 47.70 | 0.5 | 4314.9 | 4.97 |
| 2026-04-17 | SNY | 48.08 | 0.5 | 4478.8 | 4.97 |
| 2026-04-20 | SNY | 47.97 | 0.5 | 4298.1 | 4.97 |
| 2026-04-21 | SNY | 47.11 | 0.5 | 4200.5 | 4.97 |
| 2026-04-22 | SNY | 46.90 | 0.5 | 4285.6 | 4.97 |
| 2026-04-23 | SNY | 47.53 | 0.5 | 4462.1 | 4.83 |
| 2026-04-24 | SNY | 46.78 | 0.5 | 3970.1 | 4.83 |
| 2026-04-27 | SNY | 45.89 | 24.3 | 4476.6 | 4.83 |
| 2026-04-28 | SNY | 45.96 | 24.3 | 4648.6 | 4.96 |
| 2026-04-30 | SNY | 46.58 | 24.3 | 4892.0 | 4.96 |
| 2026-05-01 | SNY | 46.10 | 24.3 | 4576.7 | 4.80 |
| 2026-05-04 | SNY | 43.31 | 24.3 | 4294.8 | 4.80 |
| 2026-05-05 | SNY | 43.37 | 24.3 | 4778.2 | 4.81 |
| 2026-05-06 | SNY | 43.74 | 24.3 | 4865.3 | 4.81 |
| 2026-05-07 | SNY | 43.19 | 24.3 | 4348.9 | 4.81 |
| 2026-05-08 | SNY | 43.29 | 24.3 | 4498.9 | 4.81 |
| 2026-05-11 | SNY | 42.49 | 24.3 | 4438.2 | 4.81 |
| 2026-05-12 | SNY | 42.85 | 24.3 | 4507.7 | 4.81 |
| 2026-05-13 | SNY | 42.44 | 24.3 | 4412.5 | 4.81 |
| 2026-05-14 | SNY | 42.86 | 24.3 | 4606.5 | 4.81 |
| 2026-05-15 | SNY | 42.70 | 24.3 | 4496.0 | 4.81 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2026-04-16 | SNY | 0.00 | -4.88 | 0.31 |
| 2026-04-17 | SNY | 0.00 | -4.88 | 0.31 |
| 2026-04-20 | SNY | 0.00 | -4.92 | 0.31 |
| 2026-04-21 | SNY | 0.00 | -4.92 | 0.31 |
| 2026-04-22 | SNY | 0.00 | -4.92 | 0.31 |
| 2026-04-23 | SNY | 0.00 | -4.92 | 0.31 |
| 2026-04-24 | SNY | 0 | -4.92 | 0.31 |
| 2026-04-27 | SNY | 0 | -5.80 | 0.32 |
| 2026-04-28 | SNY | 0 | -5.80 | 0.32 |
| 2026-04-29 | SNY | 0 | -5.80 | 0.32 |
| 2026-04-30 | SNY | 0 | -5.80 | 0.32 |
| 2026-05-01 | SNY | 0 | -5.80 | 0.32 |
| 2026-05-04 | SNY | 0 | -3.12 | 0.32 |
| 2026-05-05 | SNY | 0 | -3.12 | 0.32 |
| 2026-05-06 | SNY | 0 | -3.12 | 0.32 |
| 2026-05-07 | SNY | 0 | -3.12 | 0.32 |
| 2026-05-08 | SNY | 0 | -3.12 | 0.32 |
| 2026-05-11 | SNY | 0 | -3.67 | 0.32 |
| 2026-05-12 | SNY | 0 | -3.67 | 0.33 |
| 2026-05-13 | SNY | 0 | -3.67 | 0 |
| 2026-05-14 | SNY | 0 | -3.67 | 0.33 |
| 2026-05-15 | SNY | 0 | -3.67 | 0.33 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
1.1
Avg. EPS Est. Current Quarter
1.13
Avg. EPS Est. Next Quarter
1.65
Insider Transactions
Institutional Transactions
-3.67
Beta
0.31
Average Sales Estimate Current Quarter
10812
Average Sales Estimate Next Quarter
13273
Fair Value
57.33
Quality Score
91
Growth Score
78
Sentiment Score
49
Actual DrawDown %
29
Max Drawdown 5-Year %
-33.5
Target Price
53.92
P/E
17.88
Forward P/E
8.02
PEG
1.1
P/S
2.07
P/B
1.23
P/Free Cash Flow
9.78
EPS
2.39
Average EPS Est. Cur. Y
4.81
EPS Next Y. (Est.)
5.19
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
11.81
Relative Volume
0.79
Return on Equity vs Sector %
-21.7
Return on Equity vs Industry %
-31.8
EPS 1 7Days Diff
-0.1
EPS 1 30Days Diff
-0.2
EBIT Estimation
4496
◆
SNY
Healthcare
$42.69
Swing / Pullback
Buy the dip on strong trends
WEAK
RSI
34
Range 1M
7.4%
Sup Dist
0.2%
Momentum Growth
Ride accelerating trends
WEAK
EPS Yr
7%
EPS NY
6.5%
52W%
4.2%
Long-Term Value
Quality companies, undervalued
WEAK
🟢 BUY
+44.6% upside
Upside
+44.6%
Quality
91
MoS
34%
SanofiSector: Healthcare
Industry: Drug Manufacturers - General
Employees: 74846
Sanofi engages in the research, development, manufacture, and marketing of therapeutic solutions. It provides immunology and inflammation, rare diseases neurology, oncology, and other vaccines. It also offers poliomyelitis, pertussis, and haemophilus influenzae type b (Hib) pediatric vaccines; respiratory syncytial virus protection and hexavalent combination vaccines that includes hepatitis A, typhoid, yellow fever, and rabies vaccines. It has a collaboration and license agreement with Exscientia to develop up to 15 novel small-molecule for oncology and immunology; ABL Bio, Inc. to develop ABL301 for treatment of alpha-synucleinopathies; and Innate Pharma SA for cell engager program targeting B7-H3. Further, it has a collaboration agreements with Atomwise to use ATOMNET platform and Insilico Medicine to use Pharma.AI, a medicine's AI platform; Kymera Therapeutics, Inc. to develop and commercialize protein degrader therapies targeting IRAK4 in patients with immune-inflammatory diseases; Nurix Therapeutics, Inc. to develop protein degradation therapies; Denali Therapeutics Inc. to treat systemic inflammatory diseases, such as ulcerative colitis; and Adagene Inc. for development of antibody-based therapies. Additionally, it has a collaboration with Scribe Therapeutics Inc. to develop genome editing technologies; Teva Pharmaceuticals to co-develop and co-commercialize TEV'574, for treatment of ulcerative colitis and Crohn's disease; and co-promotion service agreement with Provention Bio, Inc. for the commercialization of teplizumab. The company was formerly known as Sanofi-Aventis and changed its name to Sanofi in May 2011. Sanofi was incorporated in 1994 and is headquartered in Paris, France.
SNY
Latest News
—
Caricamento notizie per SNY…
stock quote shares SNY – Sanofi Stock Price stock today
news today SNY – Sanofi stock forecast ,stock prediction 2023 2024 2025
marketwatch SNY – Sanofi yahoo finance google finance
stock history SNY – Sanofi invest stock market
stock prices SNY premarket after hours
ticker SNY fair value insiders trading